Ph.D., University of Washington, Biostatistics, 2005.
M.A., University of Massachusetts at Amherst, Mathematics, 2000.
B.A., Skidmore College, Philosophy of Physical Science and Mathematical Modeling, 1998.
Honors and Awards
2008, Travel Award, Global HIV Vaccine Enterprise, AIDS Vaccine Conference
2006, Young Investigator Award, Section on Statistics in Epidemiology, American Statistical Association
2005, Gilbert S. Omenn Graduate Student Award for Academic Excellence, School of Public Health, University of Washington
2005, Student Conference Award, International Society for Clinical Biostatistics
2005, Senior Student Award, Department of Biostatistics, University of Washington
2004, Student Paper Award, Section on Statistics and the Environment, American Statistical Association
2000, Cardiovascular Biostatistics Training Grant, National Institutes of Health
2005-2007, Postdoctoral Fellow, Johns Hopkins School of Public Health, Biostatistics
2002-2005, Research Assistant, UW/EPA NW Research Center for Particulate Air Pollution and Health
2002-2003, Research Assistant, Fred Hutchinson Cancer Research Center, Division of Public Health Sciences
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.. Biostatistics (Oxford, England).. 2016.
Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(21):2534-40.. 2016.
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.. Current opinion in virology. 17:57-65.. 2016.
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.. Gynecologic oncology. 139(2):253-260.. 2015.
Use of placebos in Phase 1 preventive HIV vaccine clinical trials.. Vaccine. 33(6):749-52.. 2015.
The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment.. Journal of the National Cancer Institute. 107(8). 2015.
Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.. Statistics in medicine. 34(27):3503-3515.. 2015.
Analysis of HLAA*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.. Journal of virology.. 2014.
Net reclassification indices for evaluating risk prediction instruments: a critical review.. Epidemiology (Cambridge, Mass.). 25(1):114-21.. 2014.
An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection.. The international journal of biostatistics.. 2014.
Net risk reclassification p values: valid or misleading? Journal of the National Cancer Institute. 106(4):dju041.. 2014.
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (London, England). 27(15):2494-6.. 2013.
New clinical trial designs for HIV vaccine evaluation.. Current opinion in HIV and AIDS. 8(5):436-41.. 2013.
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine.. 2013.
Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'.. AIDS (London, England). 27(17):2826-7.. 2013.
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (London, England). 27(6):981-89.. 2013.
A Framework for Evaluating Markers Used to Select Patient Treatment.. Medical decision making : an international journal of the Society for Medical Decision Making.. 2013.
Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection.. The Journal of infectious diseases.. 2013.
Letter to the editor.. Biostatistics (Oxford, England).. 2013.
In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities.. AIDS research and human retroviruses.. 2013.